We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics

168 hedge funds and large institutions have $987M invested in Karyopharm Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

40% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $7.99M

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

7% more funds holding

Funds holding: 157168 (+11)

4% more capital invested

Capital invested by funds: $949M → $987M (+$38.7M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.13% less ownership

Funds ownership: 5.91%5.78% (-0.13%)

Holders
168
Holders Change
+11
Holders Change %
+7.01%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
32
Increased
61
Reduced
44
Closed
21
Calls
$11.2M
Puts
$7.99M
Net Calls
+$3.23M
Net Calls Change
+$273K
Name Holding Trade Value Shares
Change
Change in
Stake
S
151
SignatureFD
Georgia
$17K +$14.4K +62 +564%
PCG
152
Private Capital Group
Connecticut
$16K
ASN
153
Advisory Services Network
Georgia
$14K
GEA
154
Glen Eagle Advisors
New Jersey
$12.5K +$1.62K +7 +15%
OSAM
155
O'Shaughnessy Asset Management
Connecticut
$12K
TIM
156
Tortoise Investment Management
New York
$12K +$11.6K +50 New
IC
157
Ikarian Capital
Texas
$12K +$12.3K +53 New
AF
158
Advisornet Financial
Minnesota
$9K
SBL
159
Sargent Bickham Lagudis
Colorado
$9K +$9.27K +40 New
HFS
160
Horizon Financial Services
North Carolina
$5K +$4.63K +20 New
KFS
161
Kelly Financial Services
Massachusetts
$3.87K
Daiwa Securities Group
162
Daiwa Securities Group
Japan
$2K -$4.4K -19 -68%
GAM
163
Gemmer Asset Management
California
$2K
US Bancorp
164
US Bancorp
Minnesota
$2K
AF
165
Allworth Financial
California
$2K +$1.62K +7 New
IAIM
166
International Assets Investment Management
Florida
$2K +$1.62K +7 New
CCMW
167
Cypress Capital Management (Wyoming)
Wyoming
$1K
AIG
168
American International Group
New York
$631 -$18.1K -78 -3%
ACA
169
Avoro Capital Advisors
New York
-$87.6M -400,000 Closed
Point72 Asset Management
170
Point72 Asset Management
Connecticut
-$5.11M -23,315 Closed
KC
171
Kingfisher Capital
North Carolina
-$1.43M -6,539 Closed
AA
172
ALPS Advisors
Colorado
-$1.37M -6,247 Closed
AQR Capital Management
173
AQR Capital Management
Connecticut
-$1.28M -5,851 Closed
CSS
174
Cubist Systematic Strategies
Connecticut
-$1.28M -5,836 Closed
SG Americas Securities
175
SG Americas Securities
New York
-$932K -4,258 Closed

KPTI Hedge Fund Activity: Q4 2020 in Review

168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2020, worth a combined $987M — up 4.1% from $949M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new KPTI positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $87.6M sold.

  • 168 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2020, up from 157 in Q3 2020.
  • Funds reported $987M of Karyopharm Therapeutics stock for Q4 2020, up 4.1% quarter-over-quarter.
  • 32 funds opened new Karyopharm Therapeutics positions in Q4 2020 and 21 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2020 was Millennium Management, an estimated $36M added.
  • The largest Karyopharm Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2020.